Impact of Discontinuation of Denosumab on Bone Health in Breast Cancer Patients

被引：0
|
作者：
Tannenbaum, Susan
Soto, Alvaro Alvarez
Taxel, Pamela
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO1-12-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO1-12-02
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy
    Lipton, Allan
    Steger, Guenther G.
    Figueroa, Jazmin
    Alvarado, Cristina
    Solal-Celigny, Philippe
    Body, Jean Jacques
    de Boer, Richard
    Berardi, Rossana
    Gascon, Pere
    Tonkin, Katia S.
    Coleman, Robert E.
    Paterson, Alexander H. G.
    Gao, Guozhi M.
    Kinsey, Amy C.
    Peterson, Mark C.
    Jun, Susie
    CLINICAL CANCER RESEARCH, 2008, 14 (20) : 6690 - 6696
  • [42] Therapeutic approaches for protecting bone health in patients with breast cancer
    Lueftner, Diana
    Niepel, Daniela
    Steger, Guenther G.
    BREAST, 2018, 37 : 28 - 35
  • [43] Bone Health History in Breast Cancer Patients on Aromatase Inhibitors
    Kwan, Marilyn L.
    Lo, Joan C.
    Tang, Li
    Laurent, Cecile A.
    Roh, Janise M.
    Chandra, Malini
    Hahn, Theresa E.
    Hong, Chi-Chen
    Sucheston-Campbell, Lara
    Hershman, Dawn L.
    Quesenberry, Charles P., Jr.
    Ambrosone, Christine B.
    Kushi, Lawrence H.
    Yao, Song
    PLOS ONE, 2014, 9 (10):
  • [44] IMPACT ON HOSPITALIZATION DERIVED FROM THE USE OF DENOSUMAB FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES SECONDARY TO BREAST CANCER IN GERMANY
    Diel, I
    Ikenberg, R.
    Cristino, J.
    Gatta, F.
    Qian, Y.
    Arellano, J.
    VALUE IN HEALTH, 2014, 17 (07) : A644 - A645
  • [45] HEALTH RESOURCE UTILIZATION OF SUBJECTS RECEIVING DENOSUMAB AND ZOLEDRONIC ACID IN A RANDOMIZED PHASE 3 TRIAL OF ADVANCED BREAST CANCER PATIENTS WITH BONE METASTASES
    Body, J. J.
    von Moos, R.
    Stopeck, A.
    Qian, Y.
    Braun, A.
    Chung, K.
    VALUE IN HEALTH, 2010, 13 (07) : A279 - A279
  • [46] PERSISTENCE AND REASONS FOR DISCONTINUATION OF DENOSUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Mizuki, S.
    Kai, T.
    Mishima, K.
    Ikeuchi, H.
    Oryoji, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1751 - 1751
  • [47] Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases
    Dupont, Jolan
    Appermans, Wesley
    Dejaeger, Marian
    Wauters, Isabelle
    Laurent, Michael R.
    Gielen, Evelien
    BONE REPORTS, 2022, 16
  • [48] Risk factors for denosumab discontinuation in patients with postmenopausal osteoporosis
    Hattori, Kyosuke
    Takahashi, Nobunori
    Kojima, Toshihisa
    Imagama, Shiro
    MODERN RHEUMATOLOGY, 2023, 33 (04) : 843 - 850
  • [49] Impact of Bisphosphonate Therapy on Oral Health in Patients with Breast and Prostate Cancer and Bone Metastases: A Comprehensive Study
    Calik, Jacek
    Calik, Katarzyna
    Sauer, Natalia
    Zdzislaw, Bogucki
    Giedziun, Piotr
    Mackiewicz, Jacek
    Murawski, Marek
    Dziegiel, Piotr
    CANCERS, 2024, 16 (06)
  • [50] EVOLUTION OF TURNOVER BONE MARKERS AFTER DENOSUMAB DISCONTINUATION: A PRELIMINARY STUDY
    Lamy, O. L.
    Hans, D. H.
    Rodriguez, E. G. -R. Gonzalez
    Aubry-Rozier, B. A. -R.
    Stoll, D. S.
    OSTEOPOROSIS INTERNATIONAL, 2017, 28 : S526 - S526
12345